Cathepsin C Inhibitors via Local Quality and Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with dipeptidyl peptidase I (DPPI) activity, such as respiratory diseases, lack effective inhibitors that can selectively target Cathepsin C without affecting other cysteine proteases, and existing compounds may not possess desirable pharmacokinetic properties.
Innovation Solution
Development of 2-Aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides that act as potent Cathepsin C inhibitors with high selectivity against other Cathepsins, like Cathepsin K, and exhibit favorable pharmacokinetic properties, formulated into pharmaceutical compositions for treatment and prevention of diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing peptidyl nitrile inhibitors are used to target DPPI, then some inhibition activity is achieved, but selectivity against other cysteine proteases is insufficient and pharmacokinetic properties are not optimal
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at defined positions on the nitrile inhibitor core structure. The R1, R2, and R3 substituents are strategically placed to create localized interactions that enhance binding affinity for Cathepsin C while discriminating against other cysteine proteases, thus improving selectivity without sacrificing inhibition activity.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent types, positions, and steric properties on the nitrile inhibitor scaffold. This allows optimization of the inhibitor's pharmacokinetic properties and selectivity profile while maintaining potent Cathepsin C inhibition, resolving the contradiction between activity and selectivity.
2Reliability
If broad-spectrum DPPI inhibitors are developed, then inhibition of downstream serine proteases is achieved, but off-target effects on other proteases increase causing unwanted side effects
Solution Approach 1:
The patent applies preliminary anti-action by designing the nitrile inhibitor with pre-optimized selectivity features that prevent off-target binding before administration. The specific substituent patterns on the core structure create steric and electronic barriers that block interaction with non-Cathepsin C proteases, thereby preventing off-target effects while maintaining inhibition efficacy against the target enzyme and downstream serine proteases.
3Ease of manufacture
If compound structure is simplified for easier manufacture, then manufacturing cost decreases, but selectivity and pharmacokinetic properties deteriorate
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional modules: a core nitrile structure for Cathepsin C binding, and separate substituent positions (R1, R2, R3) that can be independently optimized for selectivity and pharmacokinetics. This modular approach allows systematic optimization of selectivity without significantly complicating the overall synthesis, as each module can be prepared and coupled using standard organic chemistry techniques.
Data Source
AI summary
This invention relates to 2-Aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. asthma and allergic diseases, gastrointestinal inflammatory diseases, eosinophilic diseases, chronic obstructive pulmonary disease, infection by pathogenic microbes, rheumatoid arthritis or atherosclerosis.